Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493153 | 1.00 | CYP3A4 (0.44) | CYP3A4POLBMEN1KMT2ALPAR3 | |
| SCHEMBL2498916 | 0.95 | CYP3A4 (0.48) | CYP3A4LPAR3LPAR1LPAR2TSHR | |
| SCHEMBL12191705 | 0.94 | CYP3A4 (0.39) | CYP3A4POLBMEN1KMT2ALPAR3 | |
| SCHEMBL2494184 | 0.93 | LPAR3 (0.44) | CYP3A4POLBMEN1KMT2ALPAR3 | |
| SCHEMBL2490786 | 0.93 | LPAR3 (0.44) | CYP3A4POLBMEN1KMT2ALPAR3 | |
| SCHEMBL12191704 | 0.88 | LPAR3 (0.40) | CYP3A4POLBMEN1KMT2ALPAR3 | |
| SCHEMBL2494369 | 0.88 | LPAR3 (0.48) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL2491641 | 0.88 | LPAR3 (0.48) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL2495604 | 0.88 | LPAR3 (0.48) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL2493216 | 0.87 | POLB (0.44) | POLBMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882694-B1 | OLIGOMERS AND POLYMERS OF THIOPHENE COMPOUNDS HAVING PHOSPHORIC ESTER AND PROCESS FOR PRODUCING THE SAME | NISSAN CHEMICAL IND LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8030438-B2 | Thiophene compound having phosphoric ester and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100019229-A1 | Thiophene compound having phosphoric ester and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1882694-A1 | THIOPHENE COMPOUND HAVING PHOSPHORIC ESTER AND PROCESS FOR PRODUCING THE SAME | Nissan Chemical Industries, Ltd. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100019229-A1 | Thiophene compound having phosphoric ester and process for producing the same | RRP12, NR2E1, TST | CYP3A4 684/4885POLB 1838/4885MEN1 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.